US Patent

US11260053 — Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions

Method of Use · Assigned to Satiogen Pharmaceuticals Inc · Expires 2031-05-26 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents to treat obesity, diabetes, and inflammatory gastrointestinal conditions.

USPTO Abstract

Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

Drugs covered by this patent

maralixibat-chloride (MARALIXIBAT CHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4187`	—	maralixibat-chloride
`U-4187`	—	maralixibat-chloride
`U-4187`	—	maralixibat-chloride
`U-4187`	—	maralixibat-chloride
`U-3974`	—	maralixibat-chloride

Patent Metadata

Patent number: US11260053
Jurisdiction: US
Classification: Method of Use
Expires: 2031-05-26
Drug substance claim: No
Drug product claim: No
Assignee: Satiogen Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.